AlphaMark Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $94K | Hold |
527
| – | – | 0.04% | 181 |
|
|
2024
Q3 | $104K | Buy |
527
+3
| +0.6% | +$560 | 0.04% | 271 |
|
|
2024
Q2 | $90K | Sell |
524
-66
| -11% | -$10.9K | 0.03% | 291 |
|
|
2024
Q1 | $107K | Buy |
590
+73
| +14% | +$12.6K | 0.04% | 269 |
|
|
2023
Q4 | $80K | Buy |
517
+29
| +6% | +$4.23K | 0.03% | 294 |
|
|
2023
Q3 | $73K | Buy |
488
+4
| +0.8% | +$587 | 0.03% | 289 |
|
|
2023
Q2 | $65K | Sell |
484
-96
| -17% | -$14.1K | 0.03% | 198 |
|
|
2023
Q1 | $92K | Sell |
580
-46
| -7% | -$7.03K | 0.04% | 172 |
|
|
2022
Q4 | $101K | Sell |
626
-172
| -22% | -$26.4K | 0.05% | 148 |
|
|
2022
Q3 | $107K | Buy |
798
+4
| +0.5% | +$574 | 0.05% | 145 |
|
|
2022
Q2 | $122K | Buy |
794
+3
| +0.4% | +$458 | 0.06% | 134 |
|
|
2022
Q1 | $128K | Sell |
791
-96
| -11% | -$13.9K | 0.05% | 154 |
|
|
2021
Q4 | $120K | Sell |
887
-146
| -14% | -$17.2K | 0.04% | 173 |
|
|
2021
Q3 | $111K | Buy |
1,033
+278
| +37% | +$31.8K | 0.04% | 176 |
|
|
2021
Q2 | $85K | Buy |
755
+4
| +0.5% | +$450 | 0.03% | 191 |
|
|
2021
Q1 | $81K | Buy |
751
+5
| +0.7% | +$535 | 0.03% | 187 |
|
|
2020
Q4 | $80K | Buy |
746
+4
| +0.5% | +$384 | 0.03% | 176 |
|
|
2020
Q3 | $65K | Sell |
742
-346
| -32% | -$32.6K | 0.03% | 180 |
|
|
2020
Q2 | $107K | Buy |
1,088
+504
| +86% | +$44.4K | 0.05% | 140 |
|
|
2020
Q1 | $44K | Buy |
584
+4
| +0.7% | +$341 | 0.02% | 193 |
|
|
2019
Q4 | $51K | Buy |
580
+4
| +0.7% | +$332 | 0.02% | 197 |
|
|
2019
Q3 | $44K | Sell |
576
-3,153
| -85% | -$216K | 0.02% | 204 |
|
|
2019
Q2 | $271K | Sell |
3,729
-452
| -11% | -$35.5K | 0.12% | 79 |
|
|
2019
Q1 | $337K | Buy |
4,181
+86
| +2% | +$7.04K | 0.14% | 71 |
|
|
2018
Q4 | $378K | Buy |
4,095
+5
| +0.1% | +$440 | 0.18% | 73 |
|
|
2018
Q3 | $387K | Sell |
4,090
-195
| -5% | -$18.5K | 0.16% | 94 |
|
|
2018
Q2 | $397K | Buy |
4,285
+201
| +5% | +$19.6K | 0.16% | 90 |
|
|
2018
Q1 | $387K | Sell |
4,084
-499
| -11% | -$54.8K | 0.17% | 85 |
|
|
2017
Q4 | $443K | Sell |
4,583
-349
| -7% | -$32.9K | 0.17% | 83 |
|
|
2017
Q3 | $438K | Sell |
4,932
-24
| -0.5% | -$1.83K | 0.19% | 75 |
|
|
2017
Q2 | $359K | Sell |
4,956
-250
| -5% | -$16.8K | 0.15% | 82 |
|
|
2017
Q1 | $339K | Buy |
5,206
+1,006
| +24% | +$63.2K | 0.16% | 84 |
|
|
2016
Q4 | $263K | Hold |
4,200
| – | – | 0.14% | 90 |
|
|
2016
Q3 | $265K | Hold |
4,200
| – | – | 0.13% | 90 |
|
|
2016
Q2 | $260K | Hold |
4,200
| – | – | 0.15% | 86 |
|
|
2016
Q1 | $240K | Buy |
4,200
+1,075
| +34% | +$59.9K | 0.13% | 86 |
|
|
2015
Q4 | $185K | Buy |
+3,125
| New | +$180K | 0.09% | 91 |
|
|
2015
Q3 | – | Sell |
-8,000
| Closed | -$538K | – | 290 |
|
|
2015
Q2 | $538K | Buy |
+8,000
| New | +$522K | 0.3% | 69 |
|
|
2013
Q3 | – | Sell |
-8,378
| Closed | -$346K | – | 310 |
|
|
2013
Q2 | $346K | Buy |
+8,378
| New | +$366K | 0.21% | 81 |
|
Other funds holding ABBV
AlphaMark Advisors's ABBV Position: Q4 2024 in Review
AlphaMark Advisors held its AbbVie (ABBV) position steady in Q4 2024 at 527 shares worth $94K. The position accounts for 0.04% of the portfolio, ranked #181.
AlphaMark Advisors first reported a position in ABBV in Q2 2013 and has held it in 39 quarters since. The position peaked at $538K in Q2 2015. 3,745 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.
- AlphaMark Advisors held 527 shares of AbbVie worth $94K as of Q4 2024.
- AlphaMark Advisors left its AbbVie share count unchanged in Q4 2024.
- AbbVie made up 0.04% of AlphaMark Advisors's portfolio in Q4 2024, its #181 holding.
- AlphaMark Advisors first reported a position in AbbVie in Q2 2013 and has held it in 39 quarters since.
- AlphaMark Advisors's AbbVie position peaked at $538K in Q2 2015.
- 3,745 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.
Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.